CysLT1 antagonism and 5-LO inhibition protect against the reduction in FEV1 in response to aspirin challenge [3] and improve asthma control in aspirin-sensitive patients over and above the therapeutic response to glucocorticoids, an effect that is independent of baseline urinary LTE4 [18,54]. This evidence concerns the gene CYSLTR1 and asthma.